Axsome Therapeutics Inc
AXSM
查看详细走势图
152.650USD
+5.650+3.84%
收盘 12/19, 16:00（美东）报价延迟15分钟
7.68B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.84%
5天
+3.02%
1月
+6.52%
6月
+51.60%
今年开始到现在
+80.42%
1年
+68.25%
查看详细走势图
TradingKey Axsome Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Axsome Therapeutics Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名21/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价178.74。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Axsome Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
20
位分析师
买入
评级
178.737
目标均价
+21.13%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Axsome Therapeutics Inc亮点
亮点风险
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
业绩高增长
公司营业收入稳步增长，连续3年增长670.81%
利润高增长
公司净利润处于行业前列，最新年度总收入385.69M美元
估值低估
公司最新PE估值-32.68，处于3年历史低位
机构加仓
最新机构持股38.50M股，环比增加0.21%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值7.37K
Axsome Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Axsome Therapeutics Inc简介
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
公司代码AXSM
公司Axsome Therapeutics Inc
CEOTabuteau (Herriot)
网址https://www.axsome.com/
常见问题
Axsome Therapeutics Inc(AXSM)的当前股价是多少？
Axsome Therapeutics Inc(AXSM)的当前股价是 152.650。
Axsome Therapeutics Inc的股票代码是什么？
Axsome Therapeutics Inc的股票代码是AXSM。
Axsome Therapeutics Inc股票的52周最高点是多少？
Axsome Therapeutics Inc股票的52周最高点是152.940。
Axsome Therapeutics Inc股票的52周最低点是多少？
Axsome Therapeutics Inc股票的52周最低点是75.560。
Axsome Therapeutics Inc的市值是多少？
Axsome Therapeutics Inc的市值是7.68B。
Axsome Therapeutics Inc的净利润是多少？
Axsome Therapeutics Inc的净利润为-287.22M。
现在Axsome Therapeutics Inc(AXSM)的股票是买入、持有还是卖出？
根据分析师评级，Axsome Therapeutics Inc(AXSM)的总体评级为买入，目标价格为178.737。
Axsome Therapeutics Inc(AXSM)股票的每股收益（EPS TTM）是多少
Axsome Therapeutics Inc(AXSM)股票的每股收益（EPS TTM）是-4.671。
相关品种
